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HIGH-THROUGHPUT METABOLISM-INDUCED TOXICITY ASSAYS
ON A 384-PILLAR PLATE
SOO-YEON KANG
ABSTRACT
The U.S Environmental Protection Agency (EPA) launched the Transform
Tox Testing Challenge in 2016 with the goal of developing practical methods that can
be integrated into conventional high-throughput screening (HTS) assays to better
predict the toxicity of parent compounds and their metabolites in vivo. In response to
this need and to retrofit existing HTS assays for assessing metabolism-induced
toxicity of compounds, we have developed a 384-pillar plate that is complementary to
traditional 384-well plates and ideally suited for culturing human cells in three
dimensions (3D) at a microscale. Briefly, human embryonic kidney (HEK) 293 cells
in a mixture of alginate and Matrigel were printed on the 384-pillar plates using a
microarray spotter. These cells were then coupled with 384-well plates containing
nine model compounds provided by the EPA, five representative Phase I and II drug
metabolizing enzymes (DMEs), and one no enzyme control. Membrane integrity and
viability of HEK 293 cells were measured with the calcein AM and CellTiter-Glo® kit,
respectively, to determine the IC50 values of the nine parent compounds and DMEgenerated metabolites. Out of the nine compounds tested, six compounds showed
augmented toxicity with DMEs and one compound showed detoxification with a
Phase II DME. This result indicates that the 384-pillar plate platform can be used to
measure metabolism-induced toxicity of compounds with high predictivity. In
addition, the Z’ factors and the coefficient of variation (CV) measured were above 0.6
and below 14%, respectively, indicating that the assays established on the 384-pillar
plate are robust and reproducible.
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CHAPTER I
INTRODUCTION
High attrition rates of drug candidates in clinical trials and increases in
societal concerns for animal welfare have driven in vitro and in silico human
toxicology testing innovations [1]. Lead compounds selected for traditional highthroughput screenings (HTS) using two-dimensional (2D) cell monolayers and
preclinical evaluations with animal models are often inaccurate due to lacking
correlations between in vitro cell-based models and in vivo models and differences in
genetic makeup between animals and humans. The poor predictivity of in vitro
models to in vivo models is due to a lack of drug metabolism in these systems. Drugs
are primarily metabolized in the liver by a variety of drug-metabolizing enzymes
(DMEs), including cytochromes P450 (CYP450s), UDP-glucuronosyltransferases
(UGTs), sulfotransferases (SULT), glutathione S-transferases (GSTs), etc. [2][3].
These DMEs are involved in the initial clearance of drugs from the body and generate
drug metabolites; however, some of these compounds are unstable and toxic, leading
to undesirable biological consequences, not only in the liver, but in other organs as
well [4][5]. Inter-individual variability in DMEs levels and polymorphisms result in
significant diversity for drug metabolism, which eventually leads to differences in the
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response of patients to drugs and their adverse drug reactions (ADRs) [6][7].
Therefore, maintaining physiologically relevant levels of DMEs in HTS assays and
understanding the roles of these enzymes in drug metabolism are essential in human
toxicology testing. However, incorporating physiological levels of chemical
metabolism into traditional HTS assays are still challenging, as addressed in “The
Transform Tox Testing Challenge: Innovating for Metabolism” (TTTC) promoted by
the EPA and the National Institutes of Health (NIH) subsidiaries, such as the National
Center for Advancing Translational Sciences (NCATS) and the National Institute for
Environmental Health Science (NIEHS).
To address drug metabolism issues and develop better predictive toxicity
assessment tools, the National Toxicology Program (NTP), housed within the NIEHS,
has led the innovation in high-throughput in vitro assays. The data generated from the
ToxCast and Tox21 programs demonstrated methods to evaluate and prioritize the
toxicity of chemicals using a panel of assays and provided potential insight into
chemical toxicity in vivo [8][9]. In addition, the European Union Reference
Laboratory for Alternatives to Animal Testing (EURL ECVAM) of the European
Commission’s Joint Research Centre has published an article on the possible use of a
simple modelling approach to avoid the use of chronic fish testing in chemical risk
assessment [10]. The EU policies on endocrine disruptors, multiple efficacy of
chemicals, and nanomaterials are good examples, demonstrating that traditional risk
assessment is coming to an end. The EURL ECVAM intensely participates in the
research of the replacement, reduction or refinement (3R) of laboratory animals using
alternative tests [11]. Alternative test methods developed by research laboratories
have been submitted to the EURL ECVAM for reliability, robustness, and predictivity
to be widely accepted as new tools for hazard and risk assessment [10].
2

In response to this need, we have been making important contributions to
metabolism-induced toxicity assessment by using several microarray chip platforms,
including the metabolizing enzyme toxicology assay chip (MetaChip), the data
analysis toxicology assay chip (DataChip), and the transfected enzyme and
metabolism chip (TeamChip) [12-14]. However, these microarray chip platforms
were too small in size for robotic systems commonly adopted for HTS assays and
require difficult retrofitting for existing HTS assays. Thus, we have developed a new
384-pillar plate that can be coupled with standard 384-well plates for 3D cell cultures
and high-throughput, high-content imaging (HCI) assays (Figure 1). This 384-pillar
plate can be sandwiched with standard 384-well plates, compatible with existing HTS
equipment such as microtiter plate readers, which allows for rapid absorbance,
fluorescence, and luminescence measurements in situ (Figure 2). By demonstrating
cell printing technology on the 384-pillar plate, we participated in Stages I and II of
the Transform Tox Testing Challenge. To rapidly predict metabolism-induced toxicity
of compounds, we printed human embryonic kidney (HEK) 293 cells in a mixture of
alginate and Matrigel on the 384-pillar plates using a microarray spotter, which were
coupled with a 384-well plate containing model compounds from the EPA and DMEs.
Representative DMEs, including CYP3A4, CYP1A2, CYP2B6, CYP2C9, CYP2D6,
CYP2E1, and UGT1A4, have been used to emulate metabolic reactions in the human
liver and evaluate augmented toxicity and detoxification by metabolism of the
compounds.
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Figure 1. Picture of the 384-pillar plate and the 384-well plate.

Figure 2. The sandwiched 384-pillar/well plate. The close-up image shows the
cut plane of the sandwiched plate.
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CHAPTER II
LITERATURE REVIEW
2.1 Chemical Toxicity Testing
In the past year, more than 85,000 chemicals have emerged in the United States
[Toxic Substance Control Act Inventory List]. Although the number of new chemicals
continues to increase, most of these have yet to be adequately tested for their effects
on human health. Chemical toxicity is generally evaluated by using animal-based test
methods, which have provided useful information on the safety of chemicals [15][16].
However, these traditional methods are relatively expensive and low throughput,
which make it difficult to define the mechanism of action, and continue to face
mounting ethical concerns [17]. Furthermore, intra- and inter-species differences
make it difficult to extrapolate results to human outcomes [18]. Thus, there is great
interest in alternative test models for measuring potential toxicities of new chemicals.
The National Research Council (NRC) recognized the dramatic advances in molecular
and cellular biology and proposed a new roadmap in 2004, ‘A National Toxicology
Program for the 21st Century.’ This roadmap focuses on three main areas: refining
traditional toxicology
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assays, developing rapid mechanism-based predictive systems, and improving the
overall quality of data for making public health decisions. This plan placed an
increased emphasis on in vitro systems for identifying key mechanisms of chemicals
[19]. The U.S Environmental Protection Agency (EPA) faced the same difficulty of
evaluating chemical toxicity and launched the ToxCast program in 2007 [20].
ToxCast is currently in its third and final phase, during which it has tested over 1800
possibly hazard compounds [20][21]. The goal of the program is to evaluate the
toxicity of thousands of chemicals using automated HTS technologies. HTS has been
developed by the pharmaceutical industry to evaluate the biological mechanisms of
drug candidates [22]. HTS technology optimized for drug discovery is now being
transferred to toxicological screening, representing a new paradigm in toxicological
testing [23]. However, ToxCast assays have two major pitfalls. First, ToxCast assays
are extremely limited in their ability to determine the effects of metabolism on
chemical toxicity. In other words, ToxCast assays are not able to measure how a
chemical might change in toxicity (i.e., become more or less toxic) as it is processed
by our bodies. Second, ToxCast assays are limited in their ability to analyze the full
range of chemical compounds. For example, chemicals that are not soluble in the
solvent dimethyl sulfoxide (DMSO), such as heavy metals, make high-throughput
analysis more difficult.
To resolve these issues and continue working on the ToxCast results, the
Toxicology in the 21st century (Tox21) program was developed with several federal
agencies: the US EPA, the NIH, the NIH Chemical Genomics Center (NCGC), the
NTP, and the Food and Drug Administration (FDA). With this combined expertise,
over 12,000 compounds were screened [24]. Both programs have generated a broad
spectrum of high-throughput/high-content biochemical and cell-based data used to
6

predict in vivo toxicity endpoints [25]. The ToxCast and Tox21 purposes were to
create in vitro “signatures” that are relevant to in vivo toxicity and to develop
biologically predictive models based on multiple HTS assays. Combining
computational toxicology and in vitro models provide a complement approach to
identify untested environmental chemical toxicities as an alternative to animal models
for chemical safety evaluation [26]. The purpose of these programs was to move
toxicology from a predominantly observational science at the disease specific level to
a predominantly predictive science focused on a broad inclusion of target-specific,
mechanism-based biological observations. The EPA established the TTTC with the
goal of incorporating physiological levels of chemical metabolism into conventional
HTS assays to better predict toxicity of parent compounds and their metabolites in
vivo.
2.2 The Role of the Liver in Drug Metabolism
When chemicals are ingested or inhaled by living organisms, the liver is the “first
pass” organ for administered compounds [27]. The liver, which is mainly composed
of hepatocytes, contains a wide variety of enzymes to process a myriad of chemicals
[28]. The term metabolism used here is to define all transformations of drugs and
chemicals by an enzyme(s) [29]. Metabolism of environmental chemicals is
composed of two different phases. Phase I reactions involve the modification of
compounds, where hydrolysis is the most common [28]. Phase II reactions involve
conjugation reactions by transferases, which play a crucial role in increasing the
solubility of compounds in order to facilitate excretion out of body [30-32].
Metabolism of chemicals is highly affected by drug-metabolizing enzymes (DMEs)
and their isoforms. Thus, knowledge in the role of DMEs in metabolism is an
important area to assess human toxicology testing.
7

2.2.1 Phase I
Cytochrome P450 (CYP450s) enzymes are a family of monooxygenases and
play a crucial role in phase I metabolism by performing oxidation, reduction, and
hydrolysis [28][29]. CYP450 enzymes mostly focus on the initial modification of
drugs, which decrease the plasma concentration and affect the bioavailability [28][29].
During this process, phase I metabolites are generated, some of which are biological
activity to perform desired pharmacological effects [33][34]. On the other hand,
interactions of DMEs with drugs or other chemicals can inhibit other enzymes,
leading to severe toxicity or even death [35]. Furthermore, levels of CYP450 enzymes
vary among individuals, leading to broad variations of drug efficacy [36]. DMEs
typically exist in a variety of isoforms. Isoforms are enzymes that share the same
general reaction mechanism, but are encoded for by different genes [37]. Within as
many as 18 families of DMEs, there are important subfamilies and isoforms that have
substantial involvement in metabolism during drug exposure. Of the P450s, CYP1A2,
CYP2C9, CYP2C19, CYP2D6, and CYP3A4 account for the majority of drug
metabolism, with additional contribution from CYP2E1, CYP2A6, CYP2C8, and
CYP2B6 [38-40]. However, CYP450 enzymes involved in chemical metabolism can
be dangerous. Oxidation by CYP450 enzymes can also convert a parent compound
into a more highly toxic metabolite, such as a carcinogen [29][33]. Biologically
reactive intermediates by CYP450 enzymes, such as epoxides, hydroxylamines, acyl
halides, can attach to deoxyribonucleic acids (DNA) or proteins, causing cell damage
because of their inherent instability [41]. Compared to drug metabolism, CYP1A1,
CYP1A2, CYP1B1, CYP2A6, CYP2E1, and CYP3A4 were reported to have a greater
contribution to carcinogen activation rather than drug metabolism [42]. Thus,
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understanding of CYP450 enzymes is important in drug metabolism and chemical
toxicology.
2.2.2 Phase II
In Phase II, subsequent conjugation reactions (e.g. glucuronidation, sulfation,
acetylation, and the addition of amino acids and peptides, including glutathione, are
carried out by phase II enzymes, such as UDP-glucuronyltransferases (UGTs),
glutathione S-transferases (GSTs), sulfotransferases (SULTs), methyltransferases, and
aryl-amine N-acetyltransferases (NATs). Phase II biotransformation mostly leads to
detoxification of reactive metabolites and results in increased hydrophilicity, allowing
excretion of these metabolites via transporter proteins of hepatocytes [30][43]. For
example, GST catalyzes the conjugation of reduced glutathione to various
bioactivated metabolites generated by CYP450 enzymes, resulting in detoxification of
the active metabolites [43]. In another example, UGT catalyzes the conjugation of Dglucuronic acid to metabolites possessing carboxylic acid groups [43]. Both of these
reactions account for the majority of detoxification of reactive metabolites.
2.3 Existing In Vitro Toxicity Test Platforms
Currently, animal models are widely used for the prediction of in vivo drug
metabolism. However, animal models cannot correctly reflect the in vivo conditions
due to interspecies differences. In addition, animal models are difficult to use in HTS,
due to cost. Therefore, there is need for a novel, efficient, inexpensive model, which
can be applied for drug toxicity screening. In this decade, in vitro modeling has been
largely improved. In vitro models are cost-effective and suitable for large-scale
screening.

9

2.3.1 Traditional Liver-Derived In Vitro Systems
Over the past few decades, liver-derived in vitro model systems have been
developed to provide insights into in vivo drug metabolism and toxicity. Liver tissue
slices, primary hepatocytes, and immortalized cell lines are extensively used for in
vitro models of liver toxicity testing. Advantages and disadvantages of these systems
vary greatly.
Liver tissue slices can retain liver structure and preserve all the cell types
found in vivo. Thus, it is an appropriate system to correlate metabolism in vitro to in
vivo [44]. Liver slice models are stable for 20-96 hours, with slightly decreased phase
II enzyme activity and albumin production [45][46]. However, metabolic enzyme
levels are greatly reduced after 6-72 hours and cellular necrosis occurs after 48-72
hours [47-49]
Primary hepatocytes cultures are considered to be the gold standard for in
vitro toxicity testing [50]. Primary hepatocyte cultures can retain morphology and
complete liver-specific functionality, such as DMEs, similar to in vivo situations for
the short term [51]. Therefore, primary hepatocyte cultures have been used for in vitro
studies such as enzyme induction, inhibition, and drug testing [52]. Nevertheless,
primary hepatocytes cultures are expensive and difficult to obtain in large quantities
with uniform cell function for large scale toxicity screening. In addition, these models
have drastic morphological alterations and rapid loss of liver-specific functions with
variable expression levels of DMEs when the cells are maintained in monolayer
cultures [51][53]. After the cell loses liver specific functions, response to chemicals
are different to in vivo.
To maintain liver-specific functionality over long periods of time, a simple
sandwich culture was introduced. In this system, hepatocytes are placed between two
10

layers of matrix (traditionally collagen or Matrigel®) [54]. This configuration
prevented the loss of cell viability, increased enzyme activities, and mimicked in vivo
conditions [54][55]. With this platform, liver-specific functionalities or positive
effects are maintained for extended periods of time due to contributions of the
extracellular matrix (ECM) [54].
Commercially available immortalized liver-derived cell lines include HepG2,
Hep3B, and HepaRG [56][57]. The advanced cell line, HepaRG, derived from a
human hepatocellular carcinoma, can differentiate into both the biliary and hepatocyte
lineage. HepaRG cells have expression levels of liver-specific functions, including
CYPs and phase II enzymes [58]. HepaRG retains a high proliferative capacity and
improved reproducibility for experiments [58][59]. HepaRG represents a phenotype
derived from a single donor, thereby reducing its predictive value for inter-individual
variances [58].
2.3.2 Novel In Vitro Toxicity Test Platforms
With progress in the manufacturing of micro-scale channels on biocompatible
plastics, such as polydimethylsiloxane, microfluidic platforms have become valuable
for in vitro toxicity testing [60][61]. The semi-automated system called the
HepaChip®, is a highly advanced microfluidic system mimicking hepatic sinusoids
with two electrodes [62]. Schutte et al. were able to demonstrate that hepatocytes
from HepaChip® had a higher activity of DMEs, compared to those co-cultivated in
96-well plates [62]. While small volumes are required, it is limited due to its complex
system of tubing lines and reservoirs. A major advantage of microfluidic devices over
other platforms is its ability to emulate physiological conditions in vitro by providing
mechanical stress, nutrient exchange, and drug exposure [61]. The microfluidic device
was able to maintain 3D tissue-like cellular morphology and cell-specific
11

functionality of human hepatocytes [63]. However, these sophisticated systems will
have difficulty when being adjusted for high throughput [61].
Several bioreactors have been developed for toxicology studies with
hepatocytes [64]. Schmelzer et al. utilized a hollow-fiber bioreactor where cells are
seeded into the extracapillary space and are surrounded by three independent capillary
membrane systems [65]. The capillary systems are composed of porous
polyethersulphone and hydrophobic multilaminate hollow fiber membranes, which
allow for gas exchange. The capillary layers are interwoven around the extracapillary
space and two of the capillary systems are perfused in a counter-current flow with
culture medium or plasma, while the third allows for decentralized oxygenation and
supply of nutrients. Oxygen delivery to hepatocytes is essential to retain of liverspecific functions. When the cells are exposed to low oxygen concentrations, gene
expression related to liver-specific functions rapidly was decreased [66]. Hollow fiber
bioreactors increased expression of phase I and phase II enzymes and transporters
[67-70]. Miranda et al., were able to demonstrate that hepatocytes cultured in small
stirred bioreactors allow for improved functionality [71]. The bioreactors also allow
for a well-defined culture environment with control culture parameters, such as pH
and temperature [72][73]. The main disadvantage of bioreactors is that they required a
high number of cells and large amounts of reagents, increasing costs. More recent
developments concentrate on the miniaturization for routine application in research.
2.4 Mechanisms of Toxicity of Model Compounds
In the following section, we will discuss the mechanisms of toxicity of the
model compounds used in our experiment. The nine model test compounds,
benzo[a]pyrene, aflatoxin B1, cyclophosphamide, 2-naphthlyamine, acrylamide,
doxorubicin hydrochloride (HCl), 6-aminochrysene, 8-methoxypsoralen, and 412

nitrophenol were provided by the EPA. Prior to testing model compounds,
acetaminophen was used to measure the error range and the quality of the new assay.
The model compounds were selected from a wide range of carcinogens to
chemotherapy agents to induce various mechanisms of toxicity so that we could
demonstrate our ability to detect metabolism-induced toxicity on the 384-pillar plate.
2.4.1 Acetaminophen
Acetaminophen (APAP) is widely known to be an analgesic and antipyretic
medication. When APAP is ingested, there are two phases of APAP metabolism. The
majority of APAP is metabolized via CYP450s, particularly CYP2E1, CYP1A2, and
CYP3A4, to N-acetyl-p-benzoquinone imine (NAPQI), which is a highly reactive
toxic metabolite [74][75]. NAPQI can bind to membrane proteins, resulting in
oxidative stress and mitochondrial dysfunction. This leads to the disruption of
adenosine triphosphate (ATP) production, ultimately causing cell necrosis [76][77].
Another portion of APAP is neutralized via the phase II enzymes UGT and SULT to
form glucouronidated and sulfated conjugates that can be eliminated from the body
through urine [78].
2.4.2 Benzo[a]pyrene
Benzo[a]pyrene (BAP) is a carcinogen categorized as a poly-cyclic aromatic
hydrocarbon (PAH) [79]. PAH are initially lipophilic and inert, but can be activated to
become reactive molecules by DMEs [80]. The metabolism of BAP is defined by its
several conversions through CYPs subfamilies and epoxide hydrolase [79][80]. BAP
is first oxidized to Benzo[a]pyrene-7,8-oxide by CYP1A2, CYP2C9, and CYP3A4
[79-82]. Then benzo[a]pyrene-7,8-diol is produced by opening the epoxide ring [83].
Benzo[a]pyrene-7,8dihydrodiol-9,10-epoxide is the ultimate product of BAP through
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enzymatic reactions [80]. This final molecule binds to DNA and can introduce
mutations, ultimately becoming a carcinogenic process [79].
2.4.3 Aflatoxin B1
Aflatoxins are mycotoxins produced by fungi in the genus Aspergillus, like
Aspergillus flavus [84]. There are over 20 isolated aflatoxin derivatives produced by
several fungal species [84]. Aflatoxins cause acute and chronic effects after human or
animal consumption [85, IARC (1993)]. Aflatoxin B1 (AFB1) is the most toxic with
respect to the cytotoxic effects among the known mycotoxins [84][85]. AFB1 has
been demonstrated to cause oxidative damage in cultured rat hepatocytes, leading to
cell injury [86]. In the human liver, CYP3A4 and CYP1A2 play important roles in the
biotransformation of AFB1 [87]. CYP3A4 is an important enzyme that catalyzes the
reaction of AFB1 to AFB1-8,9-epoxide (AFBO), while CYP1A2 catalyzes the
reaction of AFB1 to Aflatoxin Q1 (AFQ1) [88]. The epoxide can be conjugated with
glutathione [88][89]. AFM1 and AFM2 are the metabolites formed by the
hydroxylation of AFB1 [90]. AFM1 is considered a detoxified product [91]. Another
study demonstrated AFB1 was found to be more toxic than AFM1 on intestinal cells
both before and after differentiation in Caco-2 cells, leading to membrane damage
[92].
2.4.4 Cyclophosphamide
Cyclophosphamide (CPA) is commonly used as an anticancer agent against
breast cancer and lymphomas [93]. CPA itself is a prodrug, meaning it is
therapeutically inactive. Thus, metabolites of CPA have been investigated [93].
Cyclophosphamide is initially hydroxylated to 4-hydroxycyclophosphamide and
aldophosphamide, eventually leading to the generation of the therapeutically active
phosphoramide mustard and the toxic by-product, acrolein [93][94]. Oxidation of
14

CPA occurs through one or more of the CYPs isoforms [95][96]. CYP2B6 displayed
the highest activity in CPA 4-hydroxylation activity, followed by CYP3A4 and
CYP2C19. CYP1A1, CYP2C9, and CYP3A7 contributed to low rates of CPA 4hydroxylation [96][97]. CYP3A4 is also involved in N-dechloroethylation, another
oxidative pathway [97].
2.4.5. 2-Naphthylamine
2-Naphthylamine (2-NA) is classified as a bladder carcinogen found in
cigarette smoke [98][99]. 2-NA is metabolized via N-hydroxylation and Nglucuronidation in the liver and its N-glucuronide is transported to the urinary bladder
[100]. 2-NA is metabolized via N-hydroxylation by CYP1A2 to N-hydroxy-2naphthylamine (N-OH-NA). N-OH-NA and 2-Amino-1-naphthol generate reactive
oxygen species and causes damage to DNA [101]. Enzymes in the UDPglucuronosyltransferase 1 family, including UGT1A4, can convert 2-NA and 2Hydroxyamino-naphthalene to form 2-Naphthylamine-N-beta-D-glucuronoside and 2Hydroxyamino-naphthalene-N-beta-D-glucuronoside,respectively [100-103].
2.4.6 Acrylamide
Acrylamide (AA) has been detected in high concentrations in fried and baked
starch-enriched food [104]. AA is known to be a potential carcinogen in humans and
rats [105][106]. Glycidamide (GA) is a metabolite of acrylaminde and has been
demonstrated to cause somatic cell mutagenicity in in vivo studies [107]. CYP2E1 in
the human liver is a major player in the production of GA [108]. Kurebayashi et al.
has shown that GA is more toxic than AA by measuring the decrease in hepatocyte
viability [109]. Koyama et al. has also identified that GA is much more reactive with
DNA than AA [110]. GA can be further conjugation, resulting in the formation of Nacetyl-S15

(carbamoyl-2-hydroxyethyl)cysteine and N-(R,S)-acetyl-S-(2-hydroxy-2carbamoylethyl)-cysteine by several GSTs [111-112].
2.4.7 Doxorubicin HCL
Doxorubicin (DOX), an anthracycline glycosidic anticancer drug, impairs
DNA synthesis during tumor cell division and is used for the treatment of lymphoma,
osteosarcoma, and other cancers [113]. DOX is metabolized to doxorubicinol and
both

can

be

metabolized

to

their

aglycones,

doxorubicinone

and

7-

deoxydoxorubicinone, respectively, by cytoplasmic NADPH-dependent aldo-keto
reductase [114-116]. Doxorubicinol is a more cardiotoxic metabolite of DOX [117].
2.4.8 6-Aminochrysene
6-Aminochrysene (6-AC) is characterized as a potent mutagen and
metabolized by liver CYP450S to N-hydroxylated metabolites and epoxide
intermediates [118][119]. 6-AC is bioactivated through two pathways (Nhydroxylation and epoxidation). 6-AC is mainly transformed by CYP450s via Nhydroxylation pathways. These conjugation reactions are followed by Nacetyltransferases, forming carcinogenic products [120]. Another reaction is the
diolepoxide pathway. By using S. typhimurium TA1535/pSK1002, Shimada et al.
have proven that CYP3A4 is the most important isoform involved in 6-AC activation
[121]. Yamazaki et al. have shown that CYP2B6 and CYP3A4 are involved in
actively transforming 6-AC to form reactive N-hydroxylated products, whereas
CYP1A2 catalyzes 6-AC through the diolepoxide pathway [122][123]
2.4.9 8-Methoxypsoralen
8-Methoxypsoralen (8-MOP) has been used as a photochemotherapeutic
agent, treating various skin diseases, including psoriasis [124]. 8-MOP metabolism in
human is characterized by the formation of 8-hydroxypsoralen. Deeni et al. revealed
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that CYP1B1 is abundant in human skin and is the key contributor to 8-MOP
metabolism [125]. They showed CYP1A1, CYP1A2, CYP1B1, CYP2A6 and
CYP2E1 influence 8-MOP metabolism by using E.coli membranes co-expressing
various CYP450s and CYP450 reductase.
2.4.10 4-Nitrophenol
4-Nitrophenol (4-NP) is commonly used as pesticide [126]. Ingested or
inhaled 4-NP is hydroxylated to form 4-nitrocatechol (4-NC) by CYP2E1 [127]. A
major role of the CYP2E1 in 4-NP hydroxylation in laboratory animals has been
demonstrated [128][129]. CYP2E1 is involved in the hydroxylation of 4-NP to 4-NC
in at least 85% of humans [127]. Zerilli et al. used individual CYP450s (CYP2E1,
CYP3A4, CYP3A5, and CYP2A6) with human β-lymphoblastoid cells to demonstrate
hydroxylation of 4-NP in the presence of cytochrome b5, a stimulator. CYP2E1 was
found to be the most sensitive isoforms [130]. The ability of CYP3A4 was shown to
metabolize 4-NP somewhat when complexed with cytochrome b5 [130].
2.5 Endpoints
Various mechanisms (such as redox potential, integrity of cell membrane, and
activity of cellular enzymes) were assessed to detect cell viability. Each factor
indicates a different aspect of cell health, which can be used to assess and quantify
cell viability. Indicators for cell viability have been developed to make them
compatible with fluorescence microscopes, microplate readers, or flow cytometers,
and have sensitivity, specificity, and compatibility for different cell lines.
2.5.1 Cell Membrane Integrity
Calcein acetomethoxy diacetylester (Calcein AM) is a well-known
fluorescent cell permeant dye used to measure cell viability or cytotoxicity [131].
Calcein AM has enhanced hydrophobicity compared to Calcein, allowing passive
17

diffusion through viable cell membranes. After Calcein AM permeates into the
cytoplasm, it is hydrolyzed by intracellular esterases to Calcein, which is a green
fluorescent compound. Fluorescent cells indicate intact cell membranes. Calcein does
not inhibit any cellular functions, such as proliferation. Calcein is detected with the
excitation/emission spectra of 495/515 nm.
2.5.2 Cellular ATP Levels
Mitochondria are found in all eukaryotic cells and are responsible for
generating ATP, playing a central role in living processes as an energy source.
Measuring ATP levels is a fundamental method to detect viability [132]. Historically,
firefly luciferases extracted from Photinus pyralis (LucPpy) have been used for ATP
assays [133][134]; however, LucPpy luciferase has only moderate stability in vitro
and is sensitive to environmental factors, such as pH. These characteristics prevent its
potential of developing a robust homogenous ATP assay. However, Promega has
successfully established a stable form of luciferase purified from Photuris
pennsylvanica (LucPpe2). Luciferases from LucPpe2 show improved stability,
improving the robustness of the assay. During cell death, levels of ATP drop rapidly
as metabolism shuts down and ATP is degraded by endogenous ATPases. The
CellTiter-Glo® assay generates a stable luminescent signal while simultaneously
blocking the activity of ATPases during cell lysis. The assay uses the luciferase
reaction to measure ATP as an indicator of metabolically active cells [133][134]. The
enzyme luciferase acts on luciferin in the presence of Mg2+ and ATP to provide
oxyluciferin, which emits energy in the form of luminescence [133]. Generation of a
luminescent signal is proportional to the amount of ATP present, indicating cellular
metabolic activity. The CellTiter-Glo® assay allows us to quickly and efficiently
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detect luminescence for HTS. Detection of cell viability with luciferase and
biochemical markers are powerful tools for identification of compound mechanisms.
2.6 Dose-Response Curves
The effects of DMEs can be plotted using a graph representing the
concentration of the compound versus the physiological effect, also known as a dose
response curve. To understand the effect of compound metabolites on the cells, the
logarithm of test compound concentration is plotted on the x-axis, while the
physiological response from different mechanisms is plotted on the y-axis. Doseresponse curves are able to show the IC50 values, which represent the concentrations
of compounds where 50% of the biological cellular response is inhibited.
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CHAPTER III
METHODS
3.1 Culture of Human Embryonic Kidney (HEK) 293 Cells in T-75 Flasks
As a target cell model to evaluate the performance of metabolism-induced toxicity,
HEK 293 cells from the American Tissues Culture Collection (ATCC, Rockville, MD, USA)
were used in Stage II of the TTTC. HEK 293 cells were cultured in Dulbecco’s modified

eagle medium (DMEM, Corning, Corning, NY, USA) supplemented with 10% fetal
bovine serum (Corning) and 1% penicillin/streptomycin (Gibco, Gaithersburg, MD,
USA) in T-75 flasks in a 5% CO2 incubator at 37°C and passaged when it is around
80% confluent. Cell suspensions were prepared by adding 2 mL of 0.25% trypsin in
the T-75 flask, incubating for 2 - 3 minutes at 37°C, adding 7 mL of growth media,
breaking apart big cell clumps by rigorous aspiration and dispensation, centrifuging at
500 x g for 3 minutes to form a cell pellet, removing the supernatant gently, and resuspending the cells with 2 mL of growth media. The cell number was counted with a
Moxi Z automated cell counter by loading 75 µL of the cell suspension in a Moxi Z
cassette.
3.2 Culture of HEK 293 Cells in 3D on 384-pillar Plates
To ensure robust cell spot attachment to the 384-pillar plate (Medical & Bio
Device (MBD), Republic of Korea), the surface of the 384-pillar plates was coated
with 0.01% (w/v) poly (maleic anhydride-alt-1-octadecene) (PMA-OD from Sigma20

Aldrich, St. Louis, MO, USA). Briefly, a 0.01% (w/v) PMA-OD working
solution was prepared in 50 mL conical tubes by diluting 0.1% (w/v) PMA-OD
dissolved in ethanol 10-fold with ethanol and proper mixing. The 384-pillar plates
were immersed in 20 mL of the 0.01% (w/v) PMA-OD in the lid of a 384-well plate
and then dried in a sterile bioassay plate at room temperature for 2 - 3 hours. For
robust spot attachment by ionic interactions and gelation with alginate, a 2 µL mixture
of 0.0033% poly-L-lysine (PLL from Sigma-Aldrich) and 16.66 mM barium chloride
(BaCl2 from Sigma-Aldrich) was printed on each pillar of the PMA-OD-coated 384pillar plate using a microarray spotter (S+ MicroArrayer from Advanced Technology
Inc. (ATI), Incheon, South Korea). After drying overnight, 1.5 µL of the HEK 293
cell suspension in a mixture of 0.75% low-viscosity alginate (Sigma-Aldrich) and 1
mg/mL growth factor reduced (GFR) Matrigel (Corning) at 0.67 x 10

6

HEK 293

cells/mL was printed on each pillar of the PLL-BaCl2-treated 384-pillar plate using
the S+ MicroArrayer (Figure 3). After 4 minutes of gelation on the chilling deck of
the S+ MicroArrayer, the 384-pillar plate containing 1000 HEK 293 cells per pillar
was sandwiched with a 384-well plate containing 60 µL of complete DMEM growth
medium supplemented with 10% FBS and 1% P/S in each well. After pre-incubation
for 4-6 hours to remove excess BaCl2, the 384-well plate containing the complete
growth medium was discarded and the 384-pillar plate was sandwiched overnight
with a new 384-well plate containing 40 µL of the complete DMEM growth medium
supplemented with 50 μM buthionine sulfoximine (BSO) in each well. BSO, which is
an inhibitor of gamma-glutamylcysteine synthetase, was supplemented in the growth
medium to reduce cellular levels of glutathione and increase the sensitivity of reactive
metabolites generated by DMEs [14].

21

Figure 3. Schematic of the 384-pillar plate for 3D cell culture.

3.3 Measurement of DME Activity
Prior to metabolism-induced toxicity assays with HEK 293 cells, we
confirmed activities of the DMEs with fluorogenic substrates. For CYP450 activity
assays, 2 mM stock solutions of fluorogenic substrates, including BOMCC (for
CYP2B6, CYP2C9, and CYP3A4, Invitrogen, Carsbad, CA, USA) and EOMCC (for
CYP1A2, CYP2D6, and CYP2E1, ThermoFisher) were prepared in acetonitrile. A
CYP450-NADP-regeneration system mixture of 1000 nM CYP450 isoform
(ThermoFisher), 10 mM NADP+ (ThermoFisher) in 100 mM potassium phosphate
buffer (pH 8.0), and Vivid® regeneration system (100X from ThermoFisher)
containing 333 mM glucose-6-phosphate and 30 U/mL glucose-6-phosphate
dehydrogenase in 100 mM potassium phosphate buffer (pH 8.0) was prepared at a
ratio of 2:1:1. The fluorogenic substrates were diluted 200-fold in complete DMEM to
prepare a final 10 μM of the substrates. For enzymatic reactions, 47.5 μL of 10 μM
BOMCC (or 10 μM EOMCC) was added into 384-well plates, which was followed by
adding 2.5 μL of the CYP450-NADP-regeneration system mixture (final enzyme
concentrations can be found in Table 1). The fluorescence intensity was immediately
recorded using a microtiter plate reader (Synergy H1, BioTek instruments, Winooski,
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VT, USA) at an excitation wavelength of 405 nm and an emission wavelength of 460
nm.
For the UGT activity assay, a 100 μM 4-methylumbelliferone (4-MU, SigmaAldrich) working solution was prepared by mixing 1 μL of the stock 100 mM 4-MU
in methanol with 1 mL of complete DMEM. For the enzymatic reaction, 30 μL of the
100 μM 4-MU was mixed with 1 μL of UDPGA (Corning) into 384-well plates,
which was followed by adding 2.5 μL of 5 mg/mL UGT1A4 (Corning). The
fluorescence intensity was immediately recorded using the microtiter plate reader at
an excitation wavelength of 372 nm and an emission wavelength of 445 nm.
Table 1. Activity of representative drug metabolizing enzymes (DMEs) and their
substrates.

Enzymes

Substrates

Substrate
conc.
(μM)

CYP1A2
CYP2B6
CYP2C9
CYP2D6
CYP2E1
CYP3A4

EOMCC
BOMCC
BOMCC
EOMCC
EOMCC
BOMCC

10
10
10
10
10
10

UGT1A4

4-MU

100

Enzyme
conc. [E0]

38 nM
38 nM
38 nM
38 nM
75 nM
38 nM
0.38
mg/mL

Literature
Vmax
(nM/min)

Initial rate
measured
(RFU/min)

Initial
rate/[E0]

Literature
Km
(μM) a

655
640
21
52
45
277

26
26
1
2
1
11

3
51
13
43
20
10

5
87
1
5
5
95

3045

8013

61

1500 b

a

a

The Km and Vmax values were obtained from the Vivid CYP450 screening kit
protocol provided by Thermo Fisher Scientific.
b
pmol/min/mg

3.4 Preparation of 384-well Plates Containing Test Compounds and Drug
Metabolizing Enzymes
HEK 293 cells on the 384-pillar plate were exposed to different concentrations
of compounds and DMEs. The nine test compounds, benzo[a]pyrene, aflatoxin B1,
cyclophosphamide, 2-naphthlyamine, acrylamide, doxorubicin hydrochloride (HCl),
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6-aminochrysene, 8-methoxypsoralen, and 4-nitrophenol, were obtained from the
EPA. The highest dosage of the compounds tested was 250 μM, by creating a 1:200
dilution of the 50 mM compound stock solutions in DMSO with 50 μM BSOsupplemented DMEM. Using the highest dose, 2-fold serial dilutions of the
compound were performed with 50 μM BSO-supplemented DMEM containing 0.5%
DMSO in 1.5 mL Eppendorf tubes. Eight dosages at 1:200, 1:400, 1:800, 1:1600,
1:3200, 1:6400, 1:12800, and 1:25600 dilution and one solvent-alone control (DMSO
control) were prepared for each compound. A single compound was serially diluted
and then added in sections 1 – 9 of the 384-well plate, with section 1 being a DMSO
only control (Figure 4).

Figure 4. Layout of the 384-well plate (216 spots/plate) for in-situ drug
metabolism.
For Phase I DME reactions, CYP450 solutions, including CYP3A4, CYP1A2,
CYP2B6, CYP2D6, CYP2E1, CYP2C9 (ThermoFisher), were prepared in 96-well
plates by mixing 125 µL of 1000 nM CYP450, 62.5 µL of 10 mM NADP+, and 62.5
µL of Vivid® regeneration system (100X) on ice until use. Baculosome® Plus was
used as a no enzyme control (ThermoFisher). For Phase II DME reactions, the UGT
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Reaction Mix A (25 mM UDPGA from Corning) was diluted with 50 μM BSOsupplemented DMEM to prepare a final 0.75 mM UDPGA solution. This was
followed by preparing a mixture of UGT1A4 solution using 2.5 µL of 5 mg/mL
UGT1A4 (Corning) and 31 µL of 0.75 mM UDPGA.
Finally, 30 µL of each dilution of compound were dispensed in a 384-well
plate using a multichannel pipette and 2.5 µL of the five DMEs and one baculosome®
control were printed in 6 regions of the 384-well plate (Figure 4). As shown in Figure
4, region A specifically contained the baculosome® control as a test compound only
control; regions B - E contained 4 CYP450 isoforms; and region F contained
UGT1A4 as a representative phase II enzyme. The 384-pillar plate with HEK 293
cells was then sandwiched with the 384-well plate containing one test compound and
DMEs and incubated in the 5% CO2 incubator at 37C for 24 hours (Figure 5). This
was repeated for all test compounds.

Figure 5. Schematic of the 384-well plate containing single compound with
DMEs.
3.5 Cell Staining with Calcein AM and with CellTiter-Glo® Luminescent Kit for
Assessing Membrane Integrity and Measuring Cellular ATP Levels
For cell staining, compound and DME-treated HEK 293 cells on the 384-pillar
plate were rinsed once for 10 minutes by immersing the 384-pillar plate in a fresh
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384-well plate containing 60 µL of a saline solution containing 140 mM NaCl and 20
mM CaCl2. After discarding the 384-well plate with saline solution, the 384-pillar
plate was sandwiched with a new 384-well plate containing 40 µL of 0.5 μM calcein
AM (ThermoFisher) and incubated for 1 hour in the dark. After cell staining, excess
calcein AM in the cell spots were removed by rinsing the 384-pillar plate with 60 µL
of the saline solution for 10 minutes. To obtain fluorescent images of cell spots, the
384-pillar plate was sandwiched with a fresh 384-well plate with saline solution and
scanned with the S+ Scanner (ATI, Republic of Korea), an automated epifluorescence
microscope developed for rapid image acquisition at 15 frames per second (FPS).
Green fluorescent cell images were obtained at 4X magnification with the Olympus
UPLFLN 4X (numerical aperture (NA) 0.13, f-number 26.5, and depth of field (DOF)
~ 32.3 µm) (Olympus, Tokyo, Japan) and a green filter (XF404 from Omega Optical).
ImageJ was used to extract fluorescent intensity from the images obtained.
Immediately after calcein AM staining and scanning, the cells on the 384pillar plate were immersed in 40 µL of CellTiter-Glo® luminescent cell viability kit
(Promega, Madison, WI, USA) in a 384-well plate to measure cellular ATP levels. To
induce cell lysis, the sandwiched 384-pillar/well plates were shaken on an orbital
shaker for 2 minutes. After stabilizing the luminescence for 10 minutes at room
temperature, the luminescent signals were recorded using the plate reader at an
emission wavelength of 560 nm. Overall experimental procedures are illustrated in
Figure 6.
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Figure 6. Schematic of experimental procedures for metabolism-induced toxicity
assays
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CHAPTER IV
IMAGE AND DATA ANALYSIS
4.1 Image Analysis
Since the background luminescence (or fluorescence) of completely dead
HEK 293 cells (following treatment with 70% methanol for 1 h) was negligible due to
background subtraction, the percentage of live HEK 293 cells was calculated using
the following equation:
%
where FReaction is the luminescence (or fluorescence) intensity of the reaction spot and
FMax is the luminescence (or fluorescence) intensity of fully viable cells.
To produce a conventional sigmoidal dose-response curve with response
values normalized to span the range from 0% to 100% plotted against the logarithm of
test concentration, we normalized the luminescence (or fluorescence) intensities of all
cell spots with the luminescence (or fluorescence) intensity of a 100% live cell spot (a
cell spots contacted with no compound) and converted the test compound
concentration to their respective logarithms using Prism 4 (GraphPad Software, San
Diego, CA). The sigmoidal dose-response curves (variable slope) and IC50 values (i.e.,
concentration of the compound where 50% of cell viability/growth inhibited) were
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obtained using the following equation:

where IC50 is the midpoint of the curve, H is the hill slope, X is the logarithm of test
concentration, and Y is the response (% live cells), starting from the top plateau (Top)
of the sigmoidal curve to the bottom plateau (Bottom).

4.2 Calculation of the Coefficient of Variation (CV) and the Z’ Factor
The CV is the ratio of the standard deviation (SD) to the average (Avg). It
represents variability in relation to the average signal strength, thus the inverse of the
signal-to-noise ratio [135].

To establish the robustness of the assays on the 384-pillar plate, the
reproducibility and range of error were measured using the Z’ factor and the
coefficient of variation (CV). The Z’ factor can be explained by the following
equation:

where AvgMax is the average of all maximum luminescence intensity from fully viable
HEK 293 cells on the 384-pillar plate, SDMax is the standard deviation of maximum
luminescence intensity, AvgMin is the average of all minimum luminescence intensity
from the dead cells affected by the highest dose of acetaminophen, and SDMin is the
standard deviation of minimum luminescence intensity.
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4.3 Statistical Analysis of IC50 Values
Statistical analysis was performed with GraphPad Prism 4.0 to calculate IC50
values and standard errors obtained from triplicate 384-pillar plates, with each plate
containing four replicates of each test condition. One-way analysis of variance
(ANOVA) was used to compare the mean IC50 values of test compounds obtained
from HEK 293 cells and individual DMEs. Statistically significant IC50 difference
between no enzyme control and enzyme test conditions was indicated by * for P <
0.05 and ** for P < 0.01.
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CHAPTER V
RESULTS AND ANALYSIS
5.1 Encapsulation of HEK 293 cells on the 384-pillar Plate and Measurement of
DME Activity in the 384-well Plate
Prior to testing for metabolism-induced toxicity, robust surface chemistry was
developed to prevent the detachment of HEK 293 cell spots from the surface of 384pillars. In addition, the basal toxicity of DMEs originated from cryo-protectants added
has been investigated. To minimize the basal toxicity issues, dilution ratios of DMEs
in growth media and cell seeding density have been adjusted to maintain cell viability
above 80% (data not shown). In general, a minimum of a 10-fold dilution of the stock
1000 nM DME was necessary for 1000 HEK 293 cells seeded per 384-pillar. For
robust spot attachment and cell encapsulation, the 384-pillar plate (2 mm pillar
diameter, 10.42 mm pillar height, and 4.5 mm pillar-to-pillar distance) was coated
with 0.01% PMA-OD and then treated with 0.0033% PLL and 16.66 mM BaCl2. The
maleic anhydride groups within PMA-OD were used to covalently bond the amine
groups within PLL . This surface chemistry application allowed negatively charged
alginate to bind to positively charged PLL by ionic interaction. BaCl2 was added to
the PLL solution for the gelation of the alginate matrix. An array of 216 spots (1000
HEK 293 cells
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entrapped in 1.5 μL of 0.75% alginate and 1 mg/mL Matrigel) were printed in 5
minutes using the microarray spotter. The alginate matrices with HEK 293 cells were
found to be strongly attached to the surface of 384-pillars by the applied surface
chemistry. Scanned images of the HEK 293 cells show that they had been suspended
in 3D within the alginate matrix, indicating cell encapsulation was successful (Figure
7).

Figure 7. Enlarged images of calcein AM stained HEK 293 cells on the 384-pillar
plate
Bio-printed HEK 293 cells on the 384-pillar plate were cultured in 3D by
sandwiching with a 384-well plate containing DMEM supplemented with 10 % FBS,
1 % antibiotics, and BSO. BSO was used to increase the sensitivity of reactive
metabolites generated by DMEs. After 24-hour pre-incubation, HEK 293 cells on the
384-pillar plate were exposed to nine test compounds combined with six
representative DME conditions in a new 384-well plate. For example, representative
Phase I DMEs, such as CYP1A2, CYP2B6, CYP2C9, CYP2D6, CYP2E1, and
CYP3A4, and a Phase II DME, UGT1A4, have been used (Figure 6). Lee et al.
demonstrated that encapsulated CYP450 isoforms in alginate, such as CYP1A2,
CYP3A4, and CYP2D6, were highly active [136]. The activities of all DMEs used in
this study were determined in 384-well plates prior to testing for metabolism-induced
toxicity against HEK 293 cells with nine compounds. All enzymes tested were highly
active in DMEM with the fluorescent substrates and cofactors (Figure 8 and Table 1).
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Figure 8. Enzyme activity determined with fluorogenic substrates. (A) BOMCC
substrate. (B) EOMCC substrate (C) UGT1A4 activity was measured with 4methylumbeliferone (4-MU). Fluorescence intensity decreased over time due to
transfer of the glucuronic acid component of UDPGA to 4-MU via UGT1A4.

5.2 Robustness of the Assays Established on the 384-pillar Plate
For robust assay development on the 384-pillar plate, it is important to
measure the range of errors and plate-to-plate and day-to-day reproducibility. The Z’
factor and the coefficient of variation (CV) have been commonly calculated to
evaluate the robustness and error ranges of an assay [135]. The robustness of the
CellTiter-Glo® assay on the 384-pillar plate was determined by calculating Z’ factors
with acetaminophen incubated with CYP450 isoforms. The Z’ factors calculated from
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the 384-pillar plate were between 0.57 - 0.93 (Table 2). Since the acceptable range of
the Z’ factor is between 0.5 - 1 [135][137], we concluded that the CellTiter-Glo®
luminance assay on the 384-pillar plate is robust and suitable for accurately
identifying changes in compound toxicity by DMEs. In addition, the CV values were
measured at three different dates to evaluate day-to-day variability of the CellTiterGlo® assay. The data was collected from HEK 293 cells on the 384-pillar plate
exposed to no compound and no enzyme. This method allowed us to calculate the CV
values and understand variability of cell printing and day-to-day experimental
variability (Figure 9). Our overall CV value of 13.8% indicates that the experimental
errors are within acceptable ranges (typically below 20%) for HTS [135][137].
Table 2. Robustness of the CellTiter-Glo® assay tested with acetaminophen
Test conditions

Z’ factor

IC50 values (M)

Control baculosome
CYP1A2
CYP2B6
CYP2C9
CYP2E1
CYP3A4

0.75
0.63
0.57
0.79
0.69
0.93

125.7 ± 3.3
79.1 ± 3.5
77.1 ± 3.5
66.3 ± 3.9
62.5 ± 2.6
89.2 ± 12.8

25

CV (%)

20

15

15.3%

15.0%
10

11.2%

5
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®

Figure 9. Variability of CellTiter-Glo luminance intensities obtained from
several 384-pillar plates prepared on different days
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5.3 Dose Response Curves and IC50 Values Obtained from Calcein AM Staining
and the CellTiter-Glo® Luminescence Assay
Cell membrane integrity and cellular ATP levels in HEK 293 cells on the 384pillar plate were assessed using calcein AM staining followed by a CellTiter-Glo®
assay after 24-hour exposure to various concentrations of nine compounds, five
DMEs, and one no enzyme control. Each assay was performed with nine dosages
(1.95 μM – 250 μM) in four replicates, resulting in 1944 data points (i.e., 9
compounds x 6 enzyme conditions x 9 dosages x 4 replicates). The percent of HEK
293 cells viable after 24-hour exposure to various concentrations of test compounds
and five DMEs at different dosages were compared with those of 100% viable cells
exposed to no compounds (DMSO alone control) to calculate IC50 values. We marked
IC50 values showing more than a 50% difference with the control as a meaningful
indication of metabolism-induced effects, where red-marked IC50 values indicate
compound toxicity is enhanced (augmented toxicity) due to DMEs added and bluemarked IC50 values indicate compound toxicity is reduced (detoxification) in the
presence of DMEs. Black-marked IC50 values indicate no changes in compound
toxicity in the presence of DMEs. Calcein AM, which is a fluorogenic compound, can
be transported through the cellular membrane and produce a green fluorescent signal
when the cell membrane is intact, making it useful for cell viability assessment [138].
However, it tends to be less sensitive compared to other viability endpoints, such as
mitochondrial membrane potential with tetramethyl rhodamine methyl ester or ATP
level measurement with the CellTiter-Glo® assay [139]. This cell viability assay,
which uses ATP amount detection in the cell, is the fastest and most sensitive assay
and has less artifacts than other cell viability assay methods [140].
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We also observed relatively higher IC50 values with calcein AM staining,
presumably due to cell staining immediately after 24-hour incubation with compounds
and DMEs. Nonetheless, benzo[a]pyrene, cyclophosphamide, 2-naphthlyamine, and
6-aminochrysene clearly showed augmented toxicity on multiple CYP450 isoforms
(Table 3). For example, 2-naphthlyamine incubated with CYP2E1, CYP2B6,
CYP1A2, and CYP3A4 induced striking decreases in HEK 293 cell viability (Figure
10). The dose response curves and the IC50 values of the nine compounds and their
potential DME-generated metabolites are summarized in Table 3 and Figure 11 for
calcein AM staining.
Table 3. IC50 values of compounds tested with the calcein AM assay on the 384pillar/well plates
Compounds

No
enzyme

CYP
3A4

CYP
1A2
194
± 9.8***
>250

CYP
2B6

CYP
2C9

CYP
2D6

CYP
2E1

UGT
1A4

>250

-

-

>250

>250

>250

-

>250

>250

-

>250

>250

-

>250

>250

151
±13.8***

247
± 14.3

-

-

90
±21.9**

>250

-

>250

>250

-

>250

>250

Benzo[a]pyrene

>250

>250

Aflatoxin B1

>250

>250

Cyclophosphamid
e

>250

241
± 14.6

2-Naphthlyamine

>250

Acrylamide

>250

Doxorubicin HCl

>250

241
± 19.0

-

>250

-

>250

-

>250

6-Aminochrysene

>250

80.3
± 0.9***

>250

103
± 50***

-

-

>250

>250

>250

>250

>250

-

>250

-

>250

>250

>250

>250

>250

-

>250

-

>250

>250

8Methoxypsoralen
4-Nitrophenol

163
±
35.6**
>250

*

- To determine statistically significant IC50 differences between no enzyme control
and enzyme test conditions, one-way ANOVA analysis was performed and the results
were indicated as ** for p < 0.01 and *** for p < 0.0001. No indication means p > 0.05.
- Red highlighted IC50 values indicate augmented toxicity.
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Figure 10. Metabolism-induced toxicity assays with HEK 293 cells on the 384pillar plate and drug-metabolizing enzymes (DMEs) and 2-naphtylamine in the
384-well plate: (A) Scanned images of HEK 293 cells on the 384-pillar plate (B)
Microscopic images of the 384-pillar plate with HEK 293 cells sandwiched with the
384-well plate containing 2-naphtylamine and DMEs. The white dotted square
represents the 384-well and the white dotted circle indicates the 384-pillar. (C) Dose
response curves obtained from the green fluorescent images on the 384-pillar plate.
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Figure 11. Dose response curves of compounds tested with the calcein AM assay
on the 384-pillar/well plates.
Additionally, ATP levels within HEK 293 cells in the presence and absence of
DMEs have been quantified as an indicator of metabolically active cells using the
CellTiter-Glo® luminescence assay [140]. As expected, we observed relatively lower
IC50 values with the CellTiter-Glo® luminescence assay (Table 4). Six compounds out
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of nine demonstrated metabolism-induced augmented toxicity. Benzo[a]pyrene,
cyclophosphamide,

2-naphthylamine,

doxorubicin,

6-aminochrysene,

and

8-

methoxypsoralen demonstrated augmented toxicity on either P450 isoforms or
UGT1A4. In particular, the 2-naphthlyamine, 6-aminochrysene, cyclophosphamide,
and 8-methoxypsolarentest conditions decreased more than 10-fold when added with
CYP450s, compared to Baculosome controls (Figure 12 and Figure 13). Unlike other
compounds, acrylamide was detoxified in the presence of UGT1A4 (Table 4). This
can be explained by metabolites of Phase I DMEs in vivo being conjugated by Phase
II DMEs, including UGTs, SULTs, and GSTs, leading to detoxification and rapid
excretion [141]. Two compounds, aflatoxin B1 and 4-nitrophenol, were nontoxic at
given dosages regardless of DMEs added.
Table 4. IC50 values of compounds tested with the CellTiter-Glo® assay on the
384-pillar/well plates.
Compounds

No
enzyme

Benzo[a]pyrene

>250

Aflatoxin B1
Cyclophosphami
de

>250

2-Naphthlyamine

>250

Acrylamide

186
± 10.1

CYP
3A4
229
± 12.8
>250
66
±18.3***
25
± 3.6***
164
± 23.5

Doxorubicin HCl

74
± 0.7

25
± 0.7***

-

6-Aminochrysene

93
± 10.7

9
± 3.0***

32
± 7.1***

>250

>250

>250

>250

8Methoxypsoralen
4-Nitrophenol

>250

CYP
1A2
245
± 18.2
>250

CYP
2B6
116
± 7.8***
>250
155
± 5.8***
56
± 22.5***
165
± 25.6

20
± 3.3***
-

126***
± 41.1
>250

CYP
2C9

CYP
2D6

-

-

-

-

>250

CYP
2E1
233
± 9.1
>250

UGT
1A4
>250

>250

>250

24
± 1.4***
188
± 36.2

179
± 36.9**
246
± 46.9

>250

-

-

208
± 3.3

-

12
± 3.2***

-

10
±
2.1***

11
± 1.1***

42
± 1.7***

9
± 1.7***

-

-

19
± 2.4***

26
±
12.3***

-

>250

-

-

>250

-

213
± 33
>250

>250
>250

- To determine statistically significant IC50 differences between no enzyme control
and enzyme test conditions, one-way ANOVA analysis was performed and the results
were indicated as ** for p < 0.01 and *** for p < 0.0001. No indication means p > 0.05.
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- Red highlighted IC50 values indicate augmented toxicity whereas blue highlighted
IC50 value indicates detoxification.

Figure 12. Dose response curves of compounds tested with the CellTiter-Glo®
assay on the 384-pillar/well plates.
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Figure 13. Representative IC50 values showing strong responses when CYP450
isoforms added.
-

To determine statistically significant IC50 differences between no enzyme control

and enzyme test conditions, one-way ANOVA analysis was performed and the results
were indicated as *** for p < 0.0001. No indication means p > 0.05.
To verify that our metabolism toxicity assay with the 384-pillar platform was
accurate, the results were compared with literature. For example, cyclophosphamide,
which has been widely used for chemotherapy, is also known to have severe sideeffects and toxicities to humans. The main active metabolite of cyclophosphamide, 4hydroxycyclophosphamide, is metabolized by cytochrome P450 (CYP450) isoforms,
such as CYP3A4 and CYP2B6, which directly affects cytotoxic mechanisms [142]
[143]. In our result, the 384-pillar platform was able to identify that CYP3A4 and
CYP2B6 strongly activated cellular toxicity by the conversion of cyclophosphamide
to its cytotoxic metabolite. In addition, 2-naphthlyamine is known to be a human
carcinogen based on its metabolites, including N-hydroxylamine, which is formed by
CYP450 isoforms, such as CYP3A4, CYP2E1, and CYP1A2, as well as UGT1A4.
The metabolites undergo a number of conjugation reactions forming additional
functional groups [100-103]. On the 384-pillar platform, 2-naphthlyamine was shown
to be converted to its cytotoxic metabolites by CYP3A4, CYP1A2, CYP2B6,
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CYP2E1, and UGT1A4. 2-Naphthlyamine was particularly susceptible to reactions
with CYP3A4, CYP1A2, and CYP2E1. In addition, other compounds and their
partnered DME reaction toxicities were compared to literature and found to be
congruent (Table 5). From these results, we concluded that the 384-pillar platform has
the capacity as an alternative in vitro test platform for in vivo metabolite toxicity
testing.

Table 5. Drug metabolizing enzymes (DMEs) involved in metabolism of the
compounds.
Compounds

DMEs identified from
this study

Known DMEs in
literature

References

Benzo[a]pyrene

CYP1A2, CYP2B6,
CYP2C9, CYP3A4

CYP1A2, CYP2C9,
CYP3A4

Luckert et al.,2013
Yun et al., 1992
Bauer et al., 1995

Aflatoxin B1

-

CYP1A2, CYP3A4

Dohnal et al., 2014
Guengerich et al.,
1992

Cyclophosphamide
monohydrate

CYP2B6, CYP3A4

CYP2B6, CYP2C9,
CYP3A4

Chang et al., 1993
Huang et al., 2000

UGT family

Kadlubar et al.,
1977
Pacifici et al., 1986

2-Naphthylamine

CYP1A2, CYP2B6,
CYP2E1, CYP3A4,
UGT1A4

Acrylamide

UGT1A4

CYP2E1

Settels et al., 2008

Doxorubicin HCL

CYP2B6, CYP2D6,
CYP2E1, CYP3A4,
UGT1A4

Aldo-keto reductase

Speth et al., 1988
Minotti et al., 2001

6-Aminochrysene

CYP1A2, CYP2B6,
CYP2E1, CYP3A4,
UGT1A4

CYP1A2, CYP2B6,
CYP3A4

Kadlubar et al.,
1987
Shimada et al., 1989

8Methoxypsoralen

CYP1A2

CYP1A2, CYP2E1

Deeni et al., 2013

4-Nitrophenol

-

CYP2E1, CYP3A

Zerilli et al., 1997
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CHAPTER VI
DISCUSSION AND CONCLUSIONS
There have been tremendous efforts made by regulatory agencies in the world to
better predict toxicity of chemicals in humans using in vitro and in silico methods and
to reduce the use of animals in toxicity assessment. In response to this need, our group
has been developing several microarray biochip platforms to predict metabolisminduced compound toxicity in humans: the MetaChip [12], the DataChip
[13][135][144]

and the TeamChip [14]. Although these biochip platforms are

ideally suited for miniaturized 3D cell cultures by bioprinting and rapid testing
compound metabolism, their footprint is too small for commonly used robotic
dispensing systems and cell imaging systems in HTS assays. To resolve these
compatibility issues, we have developed a 384-pillar plate, which can be combined
with 384-well plates for 3D cell cultures and compound toxicity testing. In addition,
cell images and absorbance, fluorescence, and luminescence signals from cells can be
easily obtained from HCI imagers and microtiter plate readers. With this technology
and platform, we participated in Stages I and II of the Transform Tox Testing
Challenge. The scope of the challenge was to test the nine model compounds against
HEK 293 cells and rapidly identify metabolism-mediated toxicity. To address the
scope of the work and predict metabolism-induced toxicity, we printed HEK 293 cells
in an alginate-Matrigel mixture on the 384-pillar plate, which was sandwiched into
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the 384-well plate containing combinations of compounds and DMEs. Our results
indicate that the toxicity of 78% of the test compounds were significantly changed
when DMEs were incorporated. Our 384-pillar plate offers several advantages over
more conventional 2D and 3D cell culture models (Table 6), thus providing rapid
generation of human organotypic cell cultures for compound screening and superior
data quality and predictive outcomes of drug candidates’ effects in vivo. The 384pillar plate requires relatively small amounts of cells and hydrogels (typically 1 - 2 µL)
for creating and evaluating bioprinted 3D cells. Cell encapsulation protocols
developed are flexible and allow for culturing multiple cell types from different
organs in hydrogels on the 384-pillar plate, consequently providing more insight into
potential organ-specific toxicity of compounds. Miniaturized 3D cell cultures on the
384-pillar plate may serve as disease models to provide a microenvironment that
simulates specific biochemical functions and morphological features of human tissues
found in vivo. The 384-pillar plate is compatible with standard 384-well plates and
existing HTS equipment. Highly reproducible, high-throughput precision printing
allows us to test a variety of cell culture conditions and drugs in combination, which
makes it well suited for early stage HTS of compound libraries. Cell image
acquisition from miniaturized 3D cell cultures is easy and straightforward because the
whole sample depth fits within the focus depth of a normal objective (typically 2 x or
4 x magnification). High-throughput, HCI on miniaturized 3D cell cultures can
decipher toxicodynamic and toxicokinetic traits of drugs and provide more insight
into complicated toxicology pathways and related adverse responses in early stages of
drug discovery. This unique feature of the 384-pillar plate provides the capability to
test the effects of multiple DMEs against 3D-cultured cells for metabolism-induced
compound toxicity. This predictive information on toxicity will be extremely valuable
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to minimize adverse drug responses for new and existing drugs. Thus, our approach
may potentially lead to increased drug research success rates by enabling more
effective and safer compounds to enter preclinical evaluations and clinical trials.

Table 6. Advantages of using the 384-pillar plate platform for metabolisminduced toxicity.
Advantages
Miniaturized 3D cell culture
High-throughput
metabolism-induced assays
Robust and straightforward
protocols for highthroughput compound
screening
Highly flexible and
mechanistic toxicity assays
Rapid 3D cell imaging due
to small dimensions
High predictivity of
hepatotoxicity in vivo
Cost effectiveness

Future directions
Perform co-culture or layered cell culture to better mimic
tissue structures in vivo
Incorporate other organ cell types to mimic effects of drug
metabolism in multi-organ systems (e.g., 3D-cultured
primary hepatocytes on the 384-pillar plate coupled with
brain cells in the 384-well plate)
Further improve the CV and the Z’ factor for printing
colloidal samples with improved micro-solenoid valves
Include additional high-content cell staining for elucidating
mechanisms of drug-induced toxicity
Test image acquisition with conventional high-content
imagers and further develop software for rapid 3D cell image
processing
Analyze the data obtained from the 384-pillar plate with in
vitro–in vivo correlation (IVIVC) models
Further miniaturize the assays on a higher density pillar plate

Like all other in vitro alternative models, our current approach to predict
metabolism-induced toxicity in high throughput faces several technical challenges
(Table 6). One of the biggest challenges is instability of commercially available
DMEs. Most DMEs lose their metabolic capability within 24 hours, leading to
insufficient biotransformation of test compounds. This could potentially be an issue to
identify metabolism-induced toxicity of slow-metabolizing compounds. Indeed, we
have observed no response on DMEs for aflatoxin B1 and 4-nitrophenol presumably
due to these reasons. In addition, it is difficult to test all DMEs expressed in primary
hepatocytes on the 384-pillar plate platform, although the platform is still better suited
for testing mechanistic pathways of drug metabolism. There are several other
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technical challenges, including drug diffusion, contamination of commercially
available DMEs, and basal toxicity of DMEs. However, there is plenty of room for
improvement to further perfect the technology (Table 7).

Table 7. Current challenges of the 384-pillar plate platform for metabolisminduced toxicity and potential solutions.
Challenges

Insufficient
biotransformation

Metabolite
diffusion into cells
Differential cellular
responses by
metabolites
Contamination
Basal toxicity of
DMEs

Causes
DME stability is low (i.e.,
half-life is about 2 hours for
P450s)
It may lack specific enzymes
necessary for drug
metabolism
Hydrophilic metabolites
generated outside cells may
not penetrate cell
membranes
Metabolites generated may
not rupture cell membranes
or inhibit cell growth
Commercially available
DMEs are often
contaminated with
microbials
Additives (e.g.,
cryoprotectants) in DME
solutions are cytotoxic

Potential solutions
Enhance DME stability by immobilization
of the enzymes on lipid membranes or
supplementation with cofactors (e.g.,
cytochrome b5)
Use encapsulated primary hepatocytes and
HepaRG cells instead of DMEs to provide
metabolism competence
Use hepatic cells expressing DMEs (e.g.,
TeamChip, primary hepatocytes, and
HepaRG cells)
Measure other indicators of hepatotoxicity
(e.g., mitochondrial damage, apoptosis,
steatosis, phospholipidosis, etc.)
Test contamination of commercial DMEs
prior to use, or produce DMEs in sterile
conditions
Dilute DME solutions at least 10-fold or
produce DMEs in-house with less toxic
additives

We have successfully completed Stages I and II of the TTTC with the 384pillar plate and cell printing technology and demonstrated metabolism-induced
toxicity of compounds. The 384-pillar plate is a high-throughput, cost-efficient
platform for determining the cytotoxicity of compounds and their metabolites. It is
highly flexible for 3D cell cultures and can be tailored to include any combination of
DMEs to investigate potential individual metabolic profiles. Although we only
demonstrated encapsulation of HEK 293 cells on the 384-pillar plate, the cell printing
and encapsulation technology can be easily extended to include a variety of different
human cell types to assess organ-specific toxicity. In addition, calcein AM and
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CellTiter-Glo® luminescent cell viability assays demonstrated on the 384-pillar plate
can be extended to include other HCI assays to better predict hepatotoxicity of
compounds. Changing growth media over time for 3D cell cultures and cell imaging
on the 384-pillar plate are straightforward and convenient, allowing users to monitor
changes in various cell signals in situ using HCI imagers and microtiter plate readers.
Therefore, we envision that the 384-pillar plate platform can serve as a promising
high-throughput, 3D-cell based, in vitro assay tool for predictive human toxicology.
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CHAPTER VII
FUTURE WORK
1. Sufficient Biotransformation
Commercial DMEs lose their stability within 2 hours. To give enough
biotransformation, adding encapsulated HepaRG cells or inserting cofactors such as
cytochrome b5 will increase the metabolism competence.
2. Wide range of high-content assays
We have successfully proved that the 384-pillar plate can be used to understand
metabolism-mediated toxicity. However, we only used two endpoints related to cell
viability. High-content imaging (HCI) assays are capable of quantifying several
cellular responses. Further expansion of HCI assays on the 384-pillar platform is
necessary, which will be a great benefit to understand multi-parametric mechanistic
toxicity. This effort will help us analyze multiple endpoints of environmental
chemicals such as target specific signals like mitochondrial dysfunction, DNA
impairment, and apoptosis/necrosis.
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